Zydus Cadilla has got approval for the Phase II clinical trial of a new drug. Pharmaceutical company Zydus Cadila said that it has received approval to start the next phase of trial of its new drug. Zydus company is making medicines for patients suffering from Cryopyrine-Associated Periodic Syndrome (CAPS). In clinical studies, it will be studied how effective this drug is for patients with Cryopyrine-Associated Periodic Syndrome (CAPS).
Pharmaceutical company Zydus Cadila said that with the approval, it will now be able to start Phase II clinical trials of its drug ZYIL1 in Australia on patients suffering from Cryopyrine-Associated Periodic Syndrome (CAPS). Zydus Cadila said in a statement that this clinical trial will look at how safe the drug is for patients with CAPS, how much the patient can tolerate its potential side effects and how it works in the body.
Apart from this, the effects of ZYIL1 will also be studied. In the first phase clinical trial, it was found that ZYIL1 is safe and can be tolerated by the patient’s body. After the study in the next phase, it will be clear how safe this drug is for patients with cryopyrin-associated periodic syndrome.
Cryopyrine-Associated Periodic Syndrome (CAPS) is a rare disease. Patients suffering from this disease also experience many neurological complications – such as hearing loss, migraine, headache. After becoming the drug of Zydus Cadila, it can be of great help in the treatment of such patients.